Erenumab (Aimovig)
Monoclonal antibody
Evidence outlook
Approved: Migraine
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Suppression of onset of migraine attacks in adults
- Prophylaxis of migraine in adults who have at least 4 migraine days per month
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STRIVE NCT02456740 · Migraine The trial randomly assigned 955 participants to erenumab 70 mg, erenumab 140 mg, or placebo and used quadruple blinding during the 24-week placebo-controlled phase. The clinical primary endpoint, change in monthly migraine days, was significantly better with both erenumab doses than with placebo. Registry: NCT02456740 | 3 | Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase) 2016-09-05 | Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) | Reliable signal | link ↗ |
View 4 more trials
ARISE NCT02483585 · Migraine This was a randomized, quadruple-blind, placebo-controlled trial with 577 participants. The prespecified clinical primary endpoint was met: monthly migraine days decreased by 2.88 days with erenumab versus 1.84 days with placebo, a between-group difference of 1.04 days (p<0.001). Registry: NCT02483585 | 3 | Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase) 2016-07-11 | Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase): Placebo -1.84 migraine days / month (Standard Error 0.21) | Erenumab 70 mg QM -2.88 migraine days / month (Standard Error 0.21) | Reliable signal | link ↗ |
DRAGON NCT03867201 · Migraine The trial randomized 557 participants to erenumab or placebo, with participants, care providers, and investigators masked. Its primary clinical endpoint was met: erenumab reduced monthly migraine days by 8.19 days versus 6.62 days with placebo, a between-group difference of -1.57 days (p=0.015). Registry: NCT03867201 | 3 | Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12) 2021-08-11 | Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) | Reliable signal | link ↗ |
OASIS(CM) NCT03832998 · Migraine Registry: NCT03832998 | 3 | Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP (Baseline to Week 12) 2025-01-08 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT02066415 NCT02066415 · Migraine This was a randomized, triple-blind, placebo-controlled trial in 667 adults, and both erenumab doses significantly reduced monthly migraine days versus placebo (differences -2.46 and -2.45 days, both p<0.001). It is rated below the top level because neither a sample size calculation nor a planned enrolment number was found in the sources checked. Registry: NCT02066415 | 2 | Change From Baseline in Monthly Migraine Days (4-week baseline phase and the last 4 weeks of the 12-week treatment phase) 2016-02-24 | Change in monthly migraine days (last 4 of 12 weeks): erenumab 70 mg -6.64 and 140 mg -6.63 vs placebo -4.18; differences -2.46 (95% CI -3.52 to -1.39) and -2.45 (95% CI -3.51 to -1.38), both p<0.001 (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 4 (1)
What this study did
Competitive landscape
Other CGRP receptor drugs
Atogepant (Qulipta), Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy), Zavegepant (Zavzpret). Compare all 5 CGRP receptor drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Migraine: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Erenumab (Aimovig): this drug | Approved | Monoclonal antibody | CGRP receptor | Reliable signal | NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) | |
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | Nonsteroidal Anti-inflammatory Drug, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Atogepant (Qulipta) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) | |
| Celecoxib (Elyxyb) | Approved | Small molecule | COX-2 | Partial signal | No reviewed efficacy summary in this indication | |
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine (Atzumi) | Approved | Small molecule | 5-HT1D receptor | Partial signal | NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed | |
| Dihydroergotamine Mesylate (Brekiya) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (D.H.E. 45) | ApprovedUS marketing discontinued | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (Migranal) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eletriptan (Relpax) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7) | |
| Ergotamine / Caffeine (Cafergot) | ApprovedUS marketing discontinued | Small molecule | Alpha-adrenergic receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fremanezumab (Ajovy) | Approved | Monoclonal antibody | CGRP ligand | Partial signal | NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results). | |
| Frovatriptan (Frova) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Galcanezumab (Emgality) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001. | |
| Ibuprofen (Advil Migraine) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Meloxicam / Rizatriptan (Symbravo) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Reliable signal | Featured results are safety only in this race | |
| Naratriptan (Amerge) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| onabotulinumtoxinA (Botox) | Approved | Biologic (subtype unspecified) | Acetylcholine Release Inhibitor, acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Rimegepant (Nurtec ODT) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) | |
| Rizatriptan (Maxalt) | Approved | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Rizatriptan (RizaFilm) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Onzetra Xsail) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Tosymra) | Approved | Small molecule | 5-HT1B/1D receptor | Weak signal | Featured results are safety only in this race | |
| Sumatriptan Succinate (Sumavel DosePro) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zembrace SymTouch) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Injection (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Nasal Spray (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Tablets (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan / Naproxen Sodium (Treximet) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Weak signal | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Ubrogepant (Ubrelvy) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants | |
| Zavegepant (Zavzpret) | Approved | Small molecule | CGRP receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig Nasal Spray) | Approved | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Almotriptan (Axert) | US approval withdrawn | Small molecule | 5-HT1B/1D receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Elismetrep | Phase 3 | — | TRPM8 | not yet graded | No reviewed efficacy summary in this indication | |
| IncobotulinumtoxinA (Xeomin) | Phase 3 | Protein / enzyme therapeutic | acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Rizatriptan / Naproxen | Phase 3 | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Naltrexone / Acetaminophen (ALLOD-2) | Phase 2/3 | — | Opioid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BHV-2100 | Phase 2 | — | TRPM3 | not yet graded | No reviewed efficacy summary in this indication | |
| EVO756 | Phase 2 | Small molecule | MRGPRX2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-2002 | —(overall) | Undisclosed | PAR-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv) | —(overall) | — | 5-HT1D receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina) | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lasmiditan (Reyvow) | Discontinued | Small molecule | 5-HT1F receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal) | Discontinued | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zecuity) | Discontinued | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy and safety only in this race | |
| Sumatriptan Succinate Auto-Injector (Alsuma) | Discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig) | Discontinued | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Erenumab (Aimovig) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.